A federal judge has blocked the Colorado Prescription Drug Affordability Board from enforcing a first-in-the-nation upper payment limit on a blockbuster drug sold by Amgen, ruling that the pharmaceutical company is "likely to be significantly harmed" by the restriction. The decision is a significant early victory for the drug industry against a new class of state-level price control mechanisms — and a test of how far states can actually go.
What a Drug Affordability Board Does
A prescription drug affordability board is a state-created panel with the authority to decide whether a medicine's price is unaffordable to residents and, if so, to set a ceiling — called an upper payment limit — on what most people in that state will pay for it. Colorado established its board four years ago as drug prices kept climbing. The board has the power to select drugs it deems unaffordable and move through a formal process to impose that limit. Several other states have since created similar bodies, though each operates under its own rules and criteria.
The distinction that matters: Colorado has moved faster than any of them. It has not just named problem drugs — it has actually proceeded to upper payment limit decisions, which is what triggered this court fight.
Why the Ruling Matters Beyond Amgen
The judge's finding that Amgen faces significant likely harm establishes a legal foothold the pharmaceutical industry will use in any state that tries to follow Colorado's lead. Every affordability board watching this case now knows that a company willing to sue can at least buy time — and that a judge will weigh business harm against the public interest in lower prices.
That is the core tension the source does not resolve: whether the board's mandate to protect Colorado residents from unaffordable drug costs can survive the legal standard courts apply when companies argue imminent injury. For now, the cap is paused, not dead.
The Risk Embedded in the Win
Amgen gets a reprieve, not an acquittal. A preliminary injunction is not a final ruling, and Colorado's board still exists, still has its mandate, and still has the authority to set upper payment limits under state law. The underlying question — whether a state can override a drug company's price — remains unanswered. Other states with slower-moving affordability boards are watching. If Colorado ultimately loses in court, the model loses credibility. If Colorado wins after a longer fight, every other board moves faster.
The pharmaceutical industry calls this a victory. It is, at minimum, a delay.